Pharmaceutical history - February 3rd - Clotrimazole approval

In February 3rd 1975 the FDA approved as a new molecular entity the active pharmaceutical ingredient Clotrimazole under the trade name Lotrimin, manufactured by the pharmaceutical company SCHERING PLOUGH.

Clotrimazole, sold under the well known trade name Canesten, is a synthetic, imidazole derivate with broad-spectrum, antifungal activity used primarily in the treatment of skin, oral and vaginal candida infections. Clotrimazole inhibits biosynthesis of sterols, particularly ergosterol, an essential component of the fungal cell membrane, thereby damaging and affecting the permeability of the cell membrane. This results in leakage and loss of essential intracellular compounds, and eventually causes cell lysis.

Clotrimazole was discovered in 1969. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication

Source National Center for Biotechnology Information. PubChem Database. Clotrimazole, CID=2812, https://pubchem.ncbi.nlm.nih.gov/compound/Clotrimazole(accessed on Feb. 3, 2020)
Pharmwar © Created by Silvi Hoxha - Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)